Comparative Pharmacology
Head-to-head clinical analysis: KONVOMEP versus LYRICA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KONVOMEP versus LYRICA.
KONVOMEP vs LYRICA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fosnetupitant is a neurokinin-1 (NK1) receptor antagonist that inhibits substance P binding; palonosetron is a serotonin-3 (5-HT3) receptor antagonist that blocks emetic signals in the chemoreceptor trigger zone and gastrointestinal tract.
Binds to the α2-δ subunit of voltage-gated calcium channels, reducing calcium influx and inhibiting release of excitatory neurotransmitters including glutamate, norepinephrine, and substance P.
IV: 8 mg (as netupitant 235 mg/palonosetron 0.25 mg combination) over 15 minutes on day 1 of chemotherapy.
Oral: 75-150 mg twice daily or 50-100 mg three times daily; maximum 600 mg/day. Start at 75 mg twice daily.
None Documented
None Documented
Terminal elimination half-life: 8-12 hours in healthy adults. Extended to 18-24 hours in renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is 6.3 hours (range 5.5–6.7 hours) in patients with normal renal function. Half-life increases in renal impairment (up to 48 hours in anuria).
Renal: approximately 70% as unchanged drug; fecal: approximately 20% as metabolites; biliary: negligible.
Renal excretion of unchanged drug accounts for approximately 90% of elimination; less than 1% is secreted in feces or bile. Dose adjustment required in renal impairment (CrCl <60 mL/min).
Category C
Category C
Anticonvulsant
Anticonvulsant